ESCRS - Promises and challenges ;
ESCRS - Promises and challenges ;

Promises and challenges

Promises and challenges
Howard Larkin
Howard Larkin
Published: Friday, December 7, 2018
Pavel Stodulka MD, PhD, Beatrice Cochener-Lamard MD and Mario Nubile MD d at the ESCRS Symposium at Refractive Surgery Subspecialty Day The road to the future for our profession has never been more promising or challenging,” AAO President-Elect George A Williams MD told the opening session of the American Academy of Ophthalmology 2018 Annual Meeting in Chicago. New therapies and technologies for preserving and restoring sight are the promise. How society will pay for them is the challenge, said Dr Williams, a retina and vitreous specialist who practises in Royal Oak, Michigan, USA. In the USA, it is widely accepted that about $1 trillion of the $3.5 trillion spent annually on health care is wasted on low-value care and over-treatment, Dr Williams noted. As a result, payment is moving from a volume-based system to a value-based system. “Today ophthalmologists and all physicians practice in a world of measured performance and cost transparency. In the coming years the metrics will become more difficult and the bright light of accountability will shine even brighter,” Dr Williams said. Patients, insurers, government and businesses will have more performance data and will hold physicians accountable for delivering value. “The obvious question is what is value and who shall define it,” Dr Williams said. The positive impact that services have on individual patients’ quality of life is a critical factor – and one that ophthalmology is well prepared to demonstrate, he added. “I believe we should embrace this transition, because in a true value-based system, ophthalmology wins,” said Dr Williams, who for years has worked with government agencies on value-based care. He cited the 98% success rate of cataract surgery in restoring vision for life for a cost of less than $2,000 as an example of the value ophthalmology brings. “What we do changes lives.” Supporting data gathering through AAO’s Intelligent Research in Sight (IRIS) registry is critical to getting the word out. With more than patient records from 52 million patients to date, IRIS is the world’s largest clinical database, Dr Williams noted. With its contributions to improving the quality and effectiveness of ophthalmic care and making the case for its value to patients, IRIS has changed and will continue to change the AAO, moving it toward greater value for patients, Dr Williams said. “We have chosen the road to demonstrate the value of ophthalmic care. It will not be straight, it will not be easy. But we know where we are going.” Injuries from unapproved ocular cell injection therapies are underreported by the clinics administering them, said researchers from the University of Rochester and the University of Miami. AAO highlights • Steven T Charles MD was named AAO 2018 Laureate based on his lifetime work developing techniques and technology for vitreoretinal surgery. • Philip J Rosenfeld MD, PhD, delivered the Jackson Memorial Lecture outlining the development of anti-VEGF therapy for treating wet AMD, and the epic struggle with industry and the FDA to preserve patient access to compounded bevacizumab as an affordable alternative. • A device for delivery of ranibizumab for periods up to one year for patients with age-related macular degeneration may be available in about three years following a successful trial, said researchers at Wills Eye Hospital. The device could reduce the need for frequent intravitreal injections while improving outcomes. • Metformin, commonly used to control type 2 diabetes, may be protective against development of age-related macular degeneration, according to researchers in Taiwan. • A popular online symptom checker operated by WebMD incorrectly diagnosed ocular symptoms 74% of the time and often underestimated their severity, often leading to inappropriate recommendations for self-care, found a study by researchers at McMaster University in Canada. • Pavel Stodulka MD, PhD, Beatrice Cochener-Lamard MD and Mario Nubile MD discussed Small Incision Lenticule Extraction (SMILE) outcomes and complications at the ESCRS Symposium at Refractive Surgery Subspecialty Day.
Tags: AAO 2018
Latest Articles
Glaucoma Treatment Under Pressure

New techniques and technologies add to surgeons’ difficult decisions

Read more...

Outside the Box, Inside the Pipeline

Researchers are tackling glaucoma diagnosis and treatment from all sides.

Read more...

The EHDS Is Ready for the Green Light

If proposal is approved, Europe could see better access to, and exchange and use of, health data.

Read more...

ESCRS to Release Guidelines for Cataract and Refractive Surgery

Comprehensive approach to the safest and most effective modern surgery.

Read more...

Barry Fellowship Opens Up ‘Whole New Field of Thought’

The 2022 recipient combines theoretical and practical to learn new treatments.

Read more...

Digitalising the OR—Experience and Perspectives

Benefits include saving time and improving outcomes.

Read more...

ESCRS Heritage Programme

Visionaries past and present.

Read more...

Dynamic Measures Needed for Quality of Vision

Functional visual acuity testing and straylight metering may better reflect real-world conditions.

Read more...

What Is Stopping Digital OR Adoption?

Ophthalmologists know the benefits—now it’s time to construct the right plan.

Read more...

Time to Move Beyond Monofocal IOLs?

European surgeons appear hesitant to first offer other presbyopia-correcting options to patients.

Read more...

;